T. Rowe Price Associates
LNAI

T. Rowe Price Associates’s Lunai Bioworks LNAI Stock Holding History

T. Rowe Price Associates’s Portfolio LNAI Stock Details LNAI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-565
Closed -$25K – 3135
2025
Q1 		$25K Hold
565
– – ﹤0.01% 2994
2024
Q4 		$38K Buy
565
+366
+184% +$24.3K ﹤0.01% 2965
2024
Q3 		$8K Hold
199
– – ﹤0.01% 3001
2024
Q2 		$0 Buy
+199
New +$27.1K ﹤0.01% 3010

Other funds holding LNAI

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Jane Street
Jane Street New York $1.21T AUM 78.12% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $1.28T AUM 58.89% 1-Year Est. Return
Qube Research & Technologies (QRT)
Qube Research & Technologies (QRT) London, United Kingdom $108B AUM 37.29% 1-Year Est. Return

T. Rowe Price Associates's LNAI Position: Q2 2025 in Review

T. Rowe Price Associates sold out of Lunai Bioworks (LNAI) in Q2 2025, closing a stake of 565 shares — an estimated $25K sold.

T. Rowe Price Associates first reported a position in LNAI in Q2 2024 and held it in 4 quarters. The position peaked at $38K in Q4 2024. 42 funds tracked by Wall St. Rank hold LNAI as of Q2 2025.

  • T. Rowe Price Associates reported no remaining Lunai Bioworks position as of Q2 2025 after selling out during the quarter.
  • T. Rowe Price Associates sold 565 Lunai Bioworks shares in Q2 2025, an estimated $25K.
  • T. Rowe Price Associates first reported a position in Lunai Bioworks in Q2 2024 and held it in 4 quarters.
  • T. Rowe Price Associates's Lunai Bioworks position peaked at $38K in Q4 2024.
  • 42 funds tracked by Wall St. Rank held Lunai Bioworks as of Q2 2025.

Based on T. Rowe Price Associates's 13F filing for Q2 2025, filed 14 Aug 2025.